NTRK1 and pancreatic neoplasm: Axitinib and sorafenib, both small molecule tyrosine kinase receptor inhibitors (TKI) and aflibercept, a VEGF “trap” fusion protein, were used to target angiogenesis in advanced pancreatic cancer [58,87,96,97].